Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and COVID-19 Lung Infection A Non-interventional, Prospective, Cross-sectional Study

What this Trial Is About

Researchers are studying the progression of cardiovascular diseases in people who have survived community-acquired pneumonia, including infections from influenza and COVID-19. The study aims to understand how pneumonia and infections affect the risk of serious cardiovascular events like stroke and heart attack. It focuses on how the body's immune response and changes in the microbiome (the community of microorganisms in the body) influence disease progression, with the goal of identifying patients at higher risk and developing personalized treatments. The study observes different groups including healthy controls, individuals with cardiovascular risk factors but no severe pneumonia history, survivors of severe COVID-19 pneumonia, and survivors of severe community-acquired pneumonia. Participants undergo various assessments such as blood sampling for immune and genetic analysis, lung function tests, heart ultrasounds, ECGs, six-minute walk tests, and completion of symptom questionnaires. These evaluations occur over an extended period to monitor recovery and disease progression. Participants will be followed for up to 36 months after enrollment. Researchers will track major cardiovascular events and cardiorespiratory fitness at 6 and 36 months, along with hospitalizations, respiratory complications, quality of life, mental health, metabolic diseases, and lung and heart function. The study includes detailed monitoring of immune responses, microbiome changes, and physical health measures to better understand long-term effects after pneumonia and to identify biomarkers predicting treatment response and cardiovascular disease progression.

Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.